156 related articles for article (PubMed ID: 35130417)
1. Clinical Evidence of Chemotherapy or Endocrine Therapy Maintenance in Patients with Metastatic Breast Cancer: Meta-Analysis of Randomized Clinical Trials and Propensity Score Matching of Multicenter Cohort Study.
Ren W; Yu Y; Hong H; Wang Y; Gao Q; Chen Y; Chen P; Zhao J; Ou Q; Lin D; Fu T; Tan Y; Li C; Xie X; Ye G; Tang J; Yao H
Cancer Res Treat; 2022 Oct; 54(4):1038-1052. PubMed ID: 35130417
[TBL] [Abstract][Full Text] [Related]
2. Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes.
Carausu M; Carton M; Diéras V; Petit T; Guiu S; Gonçalves A; Augereau P; Ferrero JM; Levy C; Ung M; Desmoulins I; Debled M; Bachelot T; Pistilli B; Frenel JS; Mailliez A; Chevrot M; Cabel L
JAMA Netw Open; 2022 Dec; 5(12):e2247154. PubMed ID: 36520434
[TBL] [Abstract][Full Text] [Related]
3. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Wagner AD; Thomssen C; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer.
Yuan Y; Zhang S; Wang T; Bian L; Yan M; Yin Y; Song Y; Wen Y; Li J; Jiang Z
Chin Med J (Engl); 2023 Jun; 136(12):1459-1467. PubMed ID: 37101355
[TBL] [Abstract][Full Text] [Related]
5. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
Jacquet E; Lardy-Cléaud A; Pistilli B; Franck S; Cottu P; Delaloge S; Debled M; Vanlemmens L; Leheurteur M; Guizard AV; Laborde L; Uwer L; Jacot W; Berchery D; Desmoulins I; Ferrero JM; Perrocheau G; Courtinard C; Brain E; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2018 May; 95():93-101. PubMed ID: 29655061
[TBL] [Abstract][Full Text] [Related]
6. Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea.
Kim HK; Lee SH; Kim YJ; Park SE; Lee HS; Lim SW; Cho JH; Kim JY; Ahn JS; Im YH; Yu JH; Park YH
BMC Cancer; 2019 Jan; 19(1):84. PubMed ID: 30654765
[TBL] [Abstract][Full Text] [Related]
7. Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer:: A Network Meta-analysis.
Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
Clin Ther; 2018 Apr; 40(4):628-639.e3. PubMed ID: 29609880
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer.
Yu YF; Wang Y; Fu TP; Chen K; Liu JQ; Yao HR
Breast Cancer Res Treat; 2018 Apr; 168(2):337-348. PubMed ID: 29188398
[TBL] [Abstract][Full Text] [Related]
9. Comparison of endocrine therapy and chemotherapy as different systemic treatment modes for metastatic luminal HER2-negative breast cancer patients -A retrospective study.
Liu Q; Qiu J; Lu Q; Ma Y; Fang S; Bu B; Song L
Front Oncol; 2022; 12():873570. PubMed ID: 35957911
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis.
Kawalec P; Łopuch S; Mikrut A
Clin Breast Cancer; 2015 Apr; 15(2):90-100.e1. PubMed ID: 25441421
[TBL] [Abstract][Full Text] [Related]
11. Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens.
Cabel L; Carton M; Cheaib B; Pierga JY; Dalenc F; Mailliez A; Levy C; Jacot W; Debled M; Leheurteur M; Desmoulins I; Lefeuvre C; Gonçalves A; Uwer L; Ferrero JM; Eymard JC; Petit T; Mouret-Reynier MA; Perrocheau G; Piot I; Pérol D; Simon G; Lerebours F
Breast Cancer Res Treat; 2019 Jan; 173(2):397-406. PubMed ID: 30357526
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
Jin L; Chen K; Tan C; Li J; Luo J; Yang Y; Li Y; Li S; Zhu L; Hu Y; Liu F; You Q; Peng M; Jiang Z; Liu Q
Oncologist; 2020 Aug; 25(8):e1170-e1180. PubMed ID: 32476192
[TBL] [Abstract][Full Text] [Related]
13. Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis.
Zheng J; Wu J; Wang C; Zhuang S; Chen J; Ye F
PLoS One; 2020; 15(6):e0233571. PubMed ID: 32497134
[TBL] [Abstract][Full Text] [Related]
14. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
Bui KT; Willson ML; Goel S; Beith J; Goodwin A
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
[TBL] [Abstract][Full Text] [Related]
15. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
16. Overall survival and progression-free survival with cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in breast cancer: an updated meta-analysis of randomized controlled trials.
Tian Q; Gao H; Zhou Y; Yang J
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7252-7267. PubMed ID: 34919224
[TBL] [Abstract][Full Text] [Related]
17. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.
Wilson FR; Varu A; Mitra D; Cameron C; Iyer S
Breast Cancer Res Treat; 2017 Nov; 166(1):167-177. PubMed ID: 28752187
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.
Niraula S; Ocana A
Cancer Treat Rev; 2016 Nov; 50():168-174. PubMed ID: 27693931
[TBL] [Abstract][Full Text] [Related]
19. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
20. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.
Tripathy D; Kaufman PA; Brufsky AM; Mayer M; Yood MU; Yoo B; Quah C; Yardley D; Rugo HS
Oncologist; 2013; 18(5):501-10. PubMed ID: 23652380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]